Toggle light / dark theme

The power of polymeric coating

Nice write on polymeric coatings as a material option consider when developing implants replicating a natural electrode charge without creating damage or disruptions. Author proposes such materials could be leveraged beyond their use today and expanded to include BMI implants. Definitely, will take a closer look at.


Jeff Hendricks Biotectix outlines how polymeric coatings can help improve the performance of medical and consumer electronic devices.

Potential diabetes therapy: Engineered cells that control blood sugar

Excellent. Now, the question is “has Microsoft seen this?” as they are working on solving Diabetes too as part of their Synbio program that has already shown us their DNA Data Storage.


People with type 1 diabetes must inject themselves with insulin multiple times per day. This is because their immune system has destroyed cells in the pancreas that secrete insulin to maintain a healthy blood glucose level.

A team of bioengineers now report a possible alternative to such injections. The researchers engineered human kidney cells to act like pancreatic β cells, namely to sense blood glucose levels and produce insulin accordingly (Science 2016, DOI: 10.1126/science.aaf4006). When implanted in mice with type 1 diabetes, the cells prevent high blood glucose levels, also known as hyperglycemia.

Right now, “all we offer diabetic patients to cope with their disease is to have them measure their blood glucose levels and then inject a hormone,” says Martin Fussenegger of the Swiss Federal Institute of Technology, Zurich, who led the team that engineered the cells. Although this works, he says, getting the dose right can be tough. “We set out to pioneer a new disease treatment concept.”

A New Form of Synaptic Plasticity in Pain Pathways

Nice.


Chronic pain is thought to involve the long-lasting strengthening of synapses, akin to what happens during the formation of new memories. This phenomenon, known as long-term potentiation (LTP), is triggered when neurons on both sides of a synapse are active at the same time. But now, Jürgen Sandkühler, Medical University of Vienna, Austria, and colleagues provide evidence that LTP in nociceptive circuits arises in a different way.

By simultaneously activating two types of glial cells―astrocytes and microglia―the researchers were able to produce LTP at synapses that connect peripheral C-fibers and lamina I neurons in the dorsal horn spinal cord. They also showed that with high-frequency stimulation of C-fibers, glial cells strengthen active and inactive synapses through their release of the NMDA receptor co-agonist D-serine and the cytokine tumor necrosis factor (TNF). Moreover, these molecules traveled to distant synapses, perhaps explaining why pain hypersensitivity can develop in areas surrounding or far away from an injury.

“This paper is going to stimulate a lot of discussion that will lead to important advances for all of us in the pain field,” said Theodore Price, The University of Texas at Dallas, US, who was not involved in the study. “It raises questions for my lab in our day-to-day research that we can address immediately. That’s ultimately the true measure of a really good paper.”

Progress toward personalized treatments

More proof that Precision Medicine can predict and solve complex health issues.


Brain scans could help predict response to psychotherapy for anxiety and depression.

brain-scan-treatment-research

Nov. 10, 2016 – Brain imaging scans may one day provide useful information on the response to psychotherapy in patients with depression or anxiety, according to a review of current research in the November/December issue of the Harvard Review of Psychiatry, published by Wolters Kluwer.

Two electrons go on a quantum walk and end up in a qudit: Russian scientists find a way to reliably connect quantum elements

This is a BIG DEAL in QC, and Russian Scientists solved it.


Abstract: Scientists from the Institute of Physics and Technology of the Russian Academy of Sciences and MIPT have let two electrons loose in a system of quantum dots to create a quantum computer memory cell of a higher dimension than a qubit (a quantum bit). In their study published in Scientific Reports, the researchers demonstrate for the first time how quantum walks of several electrons can help to implement quantum computation.

“By studying the system with two electrons, we solved the problems faced in the general case of two identical interacting particles. This paves the way toward compact high-level quantum structures,” comments Leonid Fedichkin, Expert at the Russian Academy of Sciences, Vice-Director for Science at NIX (a Russian computer company), and Associate Professor at MIPT’s Department of Theoretical Physics.

In a matter of hours, a quantum computer would be able to hack through the most popular cryptosystem used even in your web browser. As far as more benevolent applications are concerned, a quantum computer would be capable of molecular modeling that takes into account all interactions between the particles involved. This in turn would enable the development of highly efficient solar cells and new drugs. To have practical applications, a quantum computer needs to incorporate hundreds or even thousands of qubits. And that is where it gets tricky.

The first-in-man clinical trial targeting Alzheimer’s Tau protein

Progress with Alzheimers and this time approaching it from the direction of Tau as a target rather than Beta Amyloid. This therapy has been tested in people and whilst it is only the first step hopefully this will lead to an effective treatment for this horrific diseases and and end to the suffering it brings.


Progress towards immunotherapies that can clear tau for Alzheimers here. Most therapies are focused on misfolded amyloid-β proteins but this particular approach targets Tau and the first in human test has proceeded!

“The authors of the study have developed a vaccine that stimulates the production of an antibody that specifically targets pathological tau, discovering its “Achilles’ heel”. It is able to do this because healthy tau undergoes a series of changes to its structure forming a new region that the antibody attacks. This new region (the “Achilles’ heel”), while not present in healthy tau, is present in diseased tau early on. Therefore, the antibody tackles all the different varieties of pathological tau. In addition to this important specificity, the antibody is coupled to a carrier molecule that generates a considerable immune response with the added benefit that it is not present in humans, thus avoiding the development of an immune reaction towards the body itself.”

#aging #crowdfundthecure

Nanorockets now available with brakes and a steering wheel

Tiny machines like nanorockets are ideal candidates for drug delivery in the human body. Chemists at Radboud University now demonstrate the first complete movement regulation of a nanorocket, by providing temperature responsive brakes. An interesting feature for practical applications, since temperature sensitivity enables the rocket to stop in diseased tissues where temperatures are higher. Nature Chemistry publishes their results on December 12.

The soft nanosystems that the bio-organic chemists at Radboud University work with self assemble, which means that they spontaneously form functional units. This allows the nanorockets to change shape, making them ideal candidates for containing cargo like medicine. ‘Our biggest challenge is to provide our nanorockets with various functionalities’, says Daniela Wilson, head of Radboud University’s Bio-organic chemistry department and Nanomedicine theme leader ‘We now demonstrate the first molecularly built brake system, enabling the rockets to start and stop at desired locations.’

Intellia gears up for human testing of CRISPR with new HQ, set to double staffers

After getting off its $100 million-plus IPO in the summer, gene editing biotech Intellia Therapeutics is getting ready for human tests of its preclinical CRISPR tech with new digs designed to help bolster its research capabilities.

The biotech, which has the backing and partnerships of the likes of Atlas, Novartis and Regeneron, is on the move as it heads over to its new lab facilities at 40 Erie Street, in Cambridge, MA.

“The field of genome editing is rapidly evolving and our work to develop therapies for patients requires that we have the infrastructure necessary for R&D growth and prepare for preclinical studies and clinical trials,” said Dr. Nessan Bermingham, CEO and founder of Intellia Therapeutics.

/* */